Fund moves
6.6%Stake
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
SILO · NASDAQ · Pharmaceutical Preparations
Silo Pharma (SILO) · oqro.io/stocks/SILO · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$1.71+0.135 (+8.57%)
Close of Nov 17, 2026, vs Nov 16 · end-of-day, not a live quote
No open-market purchase by an insider of Silo Pharma was filed in the last 90 days. The latest on record was on Dec 16, 2025.
Since 2019, Silo Pharma insiders reported 44 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 6 different years, most recently 2025.
No open-market sale by an insider of Silo Pharma (SILO) was filed with the SEC in the last 90 days.
No trade in Silo Pharma (SILO) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−72.1% (−$4.42) from Nov 17, 2025 to Nov 17, 2026 · adjusted daily closes
Adjusted close went from $6.13 on Nov 17, 2025 to $1.71 on Nov 17, 2026 (−72.1%). Disclosed in this range: 6 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Sarasota, Fl.
Last 12 months
−72.1%
Market value
$3.69M
S&P 500 +10.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 14K shares sold short (0.6% of shares outstanding), −37.6% vs the previous count, 1.1 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$0
−100.0% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $6.09M, at Sep 30, 2026
Net income, last 12 months
−$3.72M
Operating profit covers interest -112.8x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Revenue, fiscal 2025
$72K
0.0% vs the year before
Net income, fiscal 2025
−$4.23M
A loss for the year
Shares outstanding
2.16M
As of Nov 13, 2026
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Traded Dec 15, 2025 · largest single transaction ~$1.1K
Dec 15, 2025~$1.1K · 2,500 sh @ $0.42
DetailsOfficial recordDec 15, 2025~$1K · 2,500 sh @ $0.41
DetailsOfficial recordTraded Nov 20 – Nov 21, 2025 · largest single transaction ~$370
Nov 20, 2025~$370 · 1,000 sh @ $0.37
DetailsOfficial recordNov 21, 2025~$365 · 1,000 sh @ $0.365
DetailsOfficial recordPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Mitchell P. Kopin
Schedule 13G: passive · filed Nov 10, 2026 · 176K shares
Anson Funds Management LP
Schedule 13G: passive · filed Nov 16, 2026 · 104K shares
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
Insiders of Silo Pharma reported 44 open-market purchases and 0 sales since 2019; purchases in 6 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $12K7×7 trades | — |
| 2024 | $23K9×9 trades | — |
| 2023 | $28K18×18 trades | — |
| 2022 | $4.7K5×5 trades | — |
| 2021 | $3.3K2×2 trades | — |
| 2019 | $1663×3 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Against the S&P 500 over the year
Since Nov 14, 2025, SILO is down 72.4% and the index fund is up 9.0%: 81 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much SILO moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Notice of delisting or failure to meet listing rules
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.